DMDaichi Maeda

Daichi Maeda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daichi Maeda has a total of 151 co-authors. Here are the top co-authors by number of shared publications:

  • Yuya Matsue

    Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan

    20 shared publications
  • Tsutomu Sunayama

    Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

    17 shared publications
  • Taishi Dotare

    Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

    13 shared publications
  • Tohru Minamino

    Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

    12 shared publications
  • Taisuke Nakade

    Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan

    10 shared publications
  • Hiroshi Wada

    Department of Cardiovascular Medicine, Saitama Medical Center Jichi Medical University Saitama Japan

    8 shared publications

Latest Publications

  • Open Access

    Development and multi-observer validation of a histopathological scoring system for interstitial cystitis/bladder pain syndrome diagnosis

    by Yoshiyuki Akiyama, Sachin Malde, Kostika Lako, Mai Iwaya, Takeshi Uehara, Aya Niimi, Masafumi Horie, Tetsuo Ushiku, Akiteru Goto, Haruki Kume, et al.

    Purpose To develop and validate a pragmatic histopathological scoring system for interstitial cystitis/bladder pain syndrome (IC/BPS) that distinguishes Hunner-type interstitial cystitis (HIC) from bladder pain syndrome (BPS) and inflammatory non-HIC chronic cystitis mimicking Hunner lesions (“other cystitis”). Methods Bladder biopsies from 96 patients were analyzed: HIC (n = 32), BPS (n = 42), and other cystitis (n = 22; bacillus Calmette–Guérin-related, follicular, and chronic bacterial cystitis). Four pathologists (A–D; A as index/model observer) independently scored hematoxylin-eosin sections using five histopathological features (inflammation, plasma cell infiltration, eosinophil infiltration, tertiary lymphoid structures, urothelial denudation; total 0–8). ROC curves were generated for HIC vs. BPS and HIC vs. other cystitis. Youden index–derived thresholds were compared across observers to select simple integer cutoffs and define an operational three-tier classification (0–2: BPS, 3–4: indeterminate, 5–8: HIC). Diagnostic performance was assessed using AUC and contingency-table metrics. Inter-observer agreement for the three-tier classification was evaluated using Fleiss’ kappa. Results HIC vs. BPS discrimination was excellent across pathologists (AUC 0.966–0.991; pooled AUC 0.983). HIC vs. other cystitis discrimination was moderate-to-good (AUC 0.723–0.808; pooled AUC 0.738). Overall agreement for the three-tier classification was 60.4% with Fleiss’ κ = 0.657; agreement was highest for BPS and modest for other cystitis. Conclusions This hematoxylin-eosin-based scoring system enables standardized IC/BPS phenotyping, robustly separating HIC from BPS and providing a structured framework for inflammatory overlap cases, with reproducible performance across international pathologists.

  • Association Between Improvement in Left Ventricular Ejection Fraction and Prognosis of Patients with Cardiac Sarcoidosis

    by Daichi Maeda, Yuya Matsue, Yudai Fujimoto, Taishi Dotare, Tsutomu Sunayama, Kenji Yoshioka, Takeru Nabeta, Yoshihisa Naruse, Takeshi Kitai, Tatsunori Taniguchi, et al.

    Changes in the left ventricular ejection fraction (LVEF) of patients with cardiac sarcoidosis (CS) have been reported; however, the prognostic implications remain unknown. This study aimed to investigate the predictive factors for LVEF improvement in patients with CS and the association between LVEF improvement and prognosis. This was a post hoc analysis of the ILLUMINATE-CS registry, a multicenter retrospective study on CS. Patients with a baseline LVEF ≥ 50% were excluded. LVEF improvement was defined as the difference between the baseline and follow-up echocardiographic results. Patients were stratified based on tertiles of LVEF improvement: 1st (≤ 0%, least improved), 2nd (0-9%), and 3rd (> 9%, most improved) tertile groups. The primary outcome was all-cause mortality after follow-up echocardiography. Overall, 188 patients with CS (age: 62.1 ± 10.7 years; male proportion: 42.6%) were analyzed. In the multivariate linear regression analysis, narrower QRS duration, lower baseline LVEF, and no prescription of beta-blockers at baseline were independently associated with greater LVEF improvement. During the median follow-up period of 407 days, 26 deaths occurred. The Kaplan-Meier curves showed a significant difference between the 3 groups (log-rank test, P = 0.002). In the adjusted Cox proportional hazard analysis, the 1st and 2nd tertile groups showed progressively higher mortality rates than the 3rd tertile group. Independent of other variables, LVEF improvement as a continuous variable was associated with a lower mortality rate. Among patients with CS, LVEF improvement was significantly associated with favorable outcomes. LVEF should be monitored if baseline LVEF is decreased.


  • Prognostic importance of the reason for six‐minute walk test interruption in hospitalized older patients with heart failure

    by Hiroshi Saito, Daichi Maeda, Nobuyuki Kagiyama, Tsutomu Sunayama, Taishi Dotare, Yudai Fujimoto, Taisuke Nakade, Kentaro Jujo, Kazuya Saito, Kentaro Kamiya, et al.

    Aim: The six‐minute walk test (6MWT) allows patients to slow down, stop and rest as needed. However, the prognostic significance of 6MWT interruption remains unclear. Therefore, this study investigated the prognostic implications of 6MWT interruption in patients with heart failure (HF). Methods: Patients hospitalized with HF who underwent 6MWT before discharge were included. They were stratified into three groups: those who completed the 6MWT, those who interrupted the test because of dyspnea or leg fatigue and those who interrupted the test for other reasons. The primary outcome was 2‐year mortality. Results: In total, 1180 patients were analyzed; 749 completed the 6MWT, 341 interrupted it because of dyspnea or leg fatigue and 90 interrupted it for other reasons. During the 2‐year follow‐up period, 238 patients (20.2%) died. In the Kaplan–Meier analysis, 6MWT interruption due to dyspnea/leg fatigue was associated with a significantly higher 2‐year mortality rate, which remained significant even after adjustment for conventional risk factors, including the 6MWD and the Borg score measured after the 6MWT. However, 6MWT interruption for other reasons was not significantly associated with mortality. Conclusion: In hospitalized patients with HF, 6MWT interruption due to dyspnea or leg fatigue was independently associated with higher 2‐year mortality, regardless of the 6MWD. These findings suggest that 6MWT interruption might be a valuable prognostic marker for HF management. Geriatr Gerontol Int 2025; 25: 1475–1480 .

  • Sarcopenia in heart failure: Comparison of prognostic value between the Asian working Group for Sarcopenia 2014 and 2019 criteria

    by Kazuya Saito, Taisuke Nakade, Nobuyuki Kagiyama, Daichi Maeda, Yudai Fujimoto, Tsutomu Sunayama, Taishi Dotare, Kentaro Jujo, Kentaro Kamiya, Hiroshi Saito, et al.

    Aim: Sarcopenia is a prevalent comorbidity among older patients with heart failure. This study aimed to evaluate the differences between sarcopenia diagnosed using the Asian Working Group for Sarcopenia (AWGS) 2014 and 2019 criteria in older patients with heart failure.Methods: This study is a post hoc sub‐analysis of data from the FRAGILE‐HF study, a prospective, multicenter, observational study. The study included 879 patients aged >65 years who were hospitalized for heart failure decompensation and could walk at discharge. Sarcopenia was diagnosed using criteria from the AWGS 2014 (2014 model) and 2019 (2019 model). The primary outcome was 2‐year mortality.Results: Sarcopenia was identified in 186 (21.1%) patients using the 2014 model and 211 (24.0%) patients using the 2019 model. Over the 2‐year follow‐up period, 158 (18.0%) deaths occurred. Adjusted Cox proportional hazard analysis showed that sarcopenia was significantly associated with 2‐year mortality in the 2014 model, whereas only severe sarcopenia was associated with mortality in the 2019 model. Both models showed significant net reclassification improvement when sarcopenia was added to the baseline model (2014 model: 0.358, 2019 model: 0.357). However, no significant difference in net reclassification improvement was observed upon direct comparison between the two models (−0.082, P = 0.376), suggesting comparable performance.Conclusions: The 2014 model shows strong prognostic value for predicting 2‐year mortality in patients with heart failure. Although the 2019 model shows similar prognostic value, particularly for severe sarcopenia, it does not significantly outperform the 2014 model. Geriatr Gerontol Int 2025; 25: 764–771.


  • Estimated protein intake and prognosis in hospitalised heart failure: A focus on patients with and without chronic kidney disease

    by Taishi Dotare, Maeda Daichi, Yuya Matsue, Yudai Fujimoto, Tsutomu Sunayama, Takashi Iso, Taisuke Nakade, Shoichiro Yatsu, Sayaki Ishiwata, Yutaka Nakamura, et al.


  • Prognostic Value of Sarcopenia Definitions and Outcomes Consortium Criteria in Older Patients with Heart Failure

    by Taisuke Nakade, Daichi Maeda, Yuya Matsue, Nobuyuki Kagiyama, Yudai Fujimoto, Tsutomu Sunayama, Taishi Dotare, Kentaro Jujo, Kazuya Saito, Kentaro Kamiya, et al.


  • Open Access

    Prognostic value of Borg scale following 6-min walk test in hospitalized older patients with heart failure

    by Hiroshi Saito, Daichi Maeda, Nobuyuki Kagiyama, Tsutomu Sunayama, Taishi Dotare, Yudai Fujimoto, Taisuke Nakade, Kentaro Jujo, Kazuya Saito, Kentaro Kamiya, et al.

    Aims: The 6-min walk test (6MWT) is a widely accepted tool for evaluating exercise tolerance and physical capacity, and the 6-min walk distance (6MWD) is an established prognostic factor in patients with heart failure (HF). However, the prognostic implications of post-6MWT dyspnoea remain unknown. We aimed to investigate the prognostic value of Borg scores after the 6MWT in patients with HF. Methods and results: Patients hospitalized for HF who underwent the 6MWT before discharge were included. Post-test dyspnoea was assessed using the Borg scale. Patients were stratified into low and high Borg score groups based on the median Borg score. The primary outcome was 2-year mortality. Among 1185 patients analysed, the median Borg score was 12. The 6MWD was significantly shorter in the high Borg score group than in the low Borg score group. The 2-year mortality rate was 20.2%. In the Kaplan–Meier analysis, the high Borg score group demonstrated an association with 2-year mortality, which remained significant even after adjustment for conventional risk factors, including the 6MWD. Furthermore, the Borg scale provided significant net reclassification improvement to the conventional risk model incorporating 6MWD. Conclusion: In hospitalized patients with HF, post-6MWT Borg scores were associated with 2-year mortality independent of the 6MWD, providing incremental prognostic value to the 6MWD. Even if patients are able to walk long distances for 6 min, it is essential to closely observe dyspnoea immediately thereafter.


  • Prognostic Impact of Sarcopenia Assessed Using Modified Asian Working Group for Sarcopenia 2019 Criteria in Heart Failure

    by Taisuke Nakade, Daichi Maeda, Yuya Matsue, Nobuyuki Kagiyama, Yudai Fujimoto, Tsutomu Sunayama, Taishi Dotare, Kentaro Jujo, Kazuya Saito, Kentaro Kamiya, et al.


  • Open Access

    Prognostic Value of Objective Social Isolation and Loneliness in Older Patients With Heart Failure: Subanalysis of FRAGILE‐HF and Kitasato Cohort

    by Hiroshi Saito, Daichi Maeda, Nobuyuki Kagiyama, Tsutomu Sunayama, Taishi Dotare, Yudai Fujimoto, Kentaro Jujo, Kazuya Saito, Shota Uchida, Nobuaki Hamazaki, et al.

    Background: Social factors encompass a broad spectrum of nonmedical factors, including objective (social isolation [SI]) and perceived (loneliness) conditions. Although social factors have attracted considerable research attention, information regarding their impact on patients with heart failure is scarce. We aimed to investigate the prognostic impact of objective SI and loneliness in older patients with heart failure. Methods and Results: This study was conducted using the FRAGILE‐HF (Prevalence and Prognostic Value of Physical and Social Frailty in Geriatric Patients Hospitalized for Heart Failure; derivation cohort) and Kitasato cohorts (validation cohort), which included hospitalized patients with heart failure aged ≥65 years. Objective SI and loneliness were defined using the Japanese version of Lubben Social Network Scale‐6 and diagnosed when the total score for objective and perceived questions on the Lubben Social Network Scale‐6 was below the median in the FRAGILE‐HF. The primary outcome was 1‐year death. Overall, 1232 and 405 patients in the FRAGILE‐HF and Kitasato cohorts, respectively, were analyzed. Objective SI and loneliness were observed in 57.8% and 51.4% of patients in the FRAGILE‐HF and 55.4% and 46.2% of those in the Kitasato cohort, respectively. During the 1‐year follow‐up, 149 and 31 patients died in the FRAGILE‐HF and Kitasato cohorts, respectively. Cox proportional hazard analysis revealed that objective SI, but not loneliness, was significantly associated with 1‐year death after adjustment for conventional risk factors in the FRAGILE‐HF. These findings were consistent with the validation cohort. Conclusions: Objective SI assessed using the Lubben Social Network Scale‐6 may be a prognostic indicator in older patients with heart failure. Given the lack of established SI assessment methods in this population, further research is required to refine such methods.


  • Bendopnea prevalence and prognostic value in older patients with heart failure: FRAGILE-HF–SONIC-HF post hoc analysis

    by Taisuke Nakade, Daichi Maeda, Yuya Matsue, Yudai Fujimoto, Nobuyuki Kagiyama, Tsutomu Sunayama, Taishi Dotare, Kentaro Jujo, Kazuya Saito, Kentaro Kamiya, et al.

    Aims: This study aimed to investigate the prevalence, clinical characteristics, and prognostic value of bendopnea in older patients hospitalized for heart failure. Methods and results: This post hoc analysis was performed using two prospective, multicentre, observational studies: the FRAGILE-HF (main cohort) and SONIC-HF (validation cohort) cohorts. Patients were categorized based on the presence of bendopnea, which was evaluated before discharge. The primary endpoint was 2-year all-cause mortality after discharge. Among the 1243 patients (median age, 81 years; 57.2% male) in the FRAGILE-HF cohort and 225 (median age, 79 years; 58.2% men) in the SONIC-HF cohort, bendopnea was observed in 31 (2.5%) and 10 (4.4%) patients, respectively. Over a 2-year follow-up period, all-cause death occurred in 20.8 and 21.9% of the patients in the FRAGILE-HF and SONIC-HF cohorts, respectively. Kaplan–Meier survival curves demonstrated significantly higher mortality rates in patients with bendopnea than in those without bendopnea in the FRAGILE-HF (log-rank P = 0.006) and SONIC-HF cohorts (log-rank P = 0.014). Cox proportional hazard analysis identified bendopnea as an independent prognostic factor for all-cause mortality in both the FRAGILE-HF [hazard ratio (HR) 2.11, 95% confidence interval (CI) 1.18–3.78, P = 0.012] and SONIC-HF cohorts (HR 4.20, 95% CI 1.63–10.79, P = 0.003), even after adjusting for conventional risk factors. Conclusion: Bendopnea was observed in a relatively small proportion of older patients hospitalized for heart failure before discharge. However, its presence was significantly associated with an increased risk of all-cause mortality.